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Abstract
Background: Small, highly reactive molecules called reactive oxygen species (ROS) play a crucial
role in cell signalling and infection control. However, high levels of ROS can cause significant
damage to cell structure and function. Studies have shown that infection with the human
immunodeficiency virus (HIV) results in increased ROS concentrations, which can in turn lead to
faster progression of HIV infection, and cause CD4+ T-cell apoptosis. To counteract these effects,
clinical studies have explored the possibility of raising antioxidant levels, with mixed results.
Methods: In this paper, a mathematical model is used to explore this potential therapy, both
analytically and numerically. For the numerical work, we use clinical data from both HIV-negative
and HIV-positive injection drug users (IDUs) to estimate model parameters; these groups have
lower baseline concentrations of antioxidants than non-IDU controls.
Results:  Our model suggests that increases in CD4+ T cell concentrations can result from
moderate levels of daily antioxidant supplementation, while excessive supplementation has the
potential to cause periods of immunosuppression.
Conclusion: We discuss implications for HIV therapy in IDUs and other populations which may
have low baseline concentrations of antioxidants.
Background
Reactive oxygen species (ROS) are highly reactive byprod-
ucts of cellular respiration. As second messengers, they
play an important role in cell signaling and in gene regu-
lation (e.g., cytokine, growth factor, and hormone action
and secretion; ion transport; transcription; neuromodula-
tion; and apoptosis) [1,2]. ROS are also important for the
normal function of the immune system; T cells both are
influenced by and influence intracellular ROS levels. In
particular, ROS play a positive role in the proliferation of
T cells and immunological defence [1-5].
A variety of reactive oxygen species are produced through-
out the body. One particular species of interest, superox-
ide ( ), is generated in two ways and for different
reasons [5]: (1) as an accidental result of incomplete elec-
tron transfers in the electron transport chain and (2) in
activated white blood cells with the purpose of destroying
pathogens. Moreover, upon production, these   mole-
cules are rapidly metabolized into hydrogen peroxide
(H2O2), a mild oxidant, which further helps to destroy
some pathogens. Intermediate concentrations of H2O2
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(and certain other ROS) result in the activation of nuclear
factor κB (NF-κB), a transcription factor that upregulates
several cellular processes, including cell proliferation and
apoptosis [1,6,7].
Despite their positive role, reactive oxygen species can be
harmful. At normal ROS concentrations, cell function and
structure are protected from destructive interactions with
ROS by various defence mechanisms. These include the
use of both enzymatic and nonenzymatic antioxidants,
substances that significantly delay or prevent the oxida-
tion of a given substrate. Non-enzymatic antioxidants
obtained directly from the diet (i.e., glutathione, vitamins
A, C and E, and flavenoids) decrease oxygen concentra-
tions, remove catalytic metal ions and eliminate radicals
from the system [8,9]. Enzymatic antioxidants remove
ROS from the system and are not consumed by the reac-
tion. These enzymes, such as superoxide dismutases, cata-
lase and glutathione peroxide, are naturally produced by
the body [9]; oral supplements and injections are also
available [9]. In addition, antioxidants repair oxidative
damage, eliminate damaged molecules and prevent muta-
tions from occurring [8].
In the event that intracellular ROS levels increase moder-
ately, cells respond by boosting antioxidant levels and by
promoting proinflammatory gene expression [10,11].
There are two main functions of the resulting translated
proteins: (1) signaling proteins activate the immune sys-
tem by various cytokines, growth factors and chemokines,
and (2) enzymes improve a cell's response to inflamma-
tory, growth-stimulatory and apoptotic signals [11].
When ROS levels exceed a cell's antioxidant capacity, oxi-
dative stress is reached; this has the potential to cause sig-
nificant damage to DNA, proteins and lipids, and can
induce apoptosis. In addition, conditions favourable for
the pathogenesis of several diseases may be created [1].
Such high levels of ROS are generally the result of chronic
and acute inflammatory diseases or environmental stress
[10].
Individuals infected by the human immunodeficiency
virus (HIV) exhibit heightened serum concentrations of
ROS [6,10,12,13] and lowered antioxidant concentra-
tions [14]. The resulting oxidative stress affects disease
progression in several ways. First, oxidative damage to
CD4+ T cells may impair the immune system's response to
HIV [15]. Second, the well-known hallmark of HIV, the
depletion of CD4+ T cell concentration in the plasma, is
further exacerbated by oxidative stress-induced apoptosis.
Third, increased HIV transcription leading to faster disease
progression results from an increased activation of NF-κB
[6]. It has been found that while NF-κB activation is not
absolutely necessary for viral replication, it accelerates the
process 20-fold [15-17]. Moreover, it has been suggested
that NF-κB is itself activated by HIV [16]. It has been
shown that this activation of NF-κB is inhibited by anti-
oxidants (such as N-acetyl cysteine and pyrrolidine dithi-
ocarbarnate) [7].
The lowered antioxidant concentrations observed in HIV-
positive individuals are associated with micronutrient
deficiencies [14,18] which are themselves caused by a
combination of decreased nutrient intake, gastrointestinal
malabsorption, increased nutritional requirements, and
psychosocial factors [18,19]. Observational studies and
intervention trials of nutritional shortfalls in HIV-positive
individuals not receiving HAART reveal that low serum
concentrations of micronutrients such as thiamine, sele-
nium, zinc, and vitamins A, B-3, B-6, B-12, C, D, and E
have been independently linked to a weakened immune
system and a higher risk of the following: vertical trans-
mission [20], faster disease progression [21], low CD4+ T
cell counts, HIV-related diseases, and mortality [22].
Intervention trials have shown that such individuals can
benefit from micronutrient supplementation [22-24].
Among their other benefits, certain micronutrients have
antioxidant properties: carotenoids and vitamins A, C,
and E [5]. Since elevated ROS levels have been linked to
more rapid HIV progression [13,25], antioxidant supple-
mentation has been suggested [6,26] and studied [22,27-
29] as a potential complement to HIV therapy.
Despite many indications that antioxidant supplementa-
tion is beneficial in HIV-positive individuals [22,27,28], it
has been suggested that antioxidant supplementation
may not be universally recommended [22]. For example,
although reduced mortality has been shown in HIV-posi-
tive children receiving vitamin A supplementation [30],
the administration of vitamin A supplements to women
has been implicated in increased vaginal viral shedding
(no effect on risk was observed from vitamins B, C, and E)
[31], a heightened risk of mother-to-child HIV transmis-
sion [32], and hastened progression of child mortality
[30]. In addition, high doses of vitamin C supplementa-
tion have been shown to reduce the bioavailability of the
protease inhibitor, indinavir [33]. These findings, among
others, undoubtedly necessitate concern, and have led
authors to question the benefits of universal vitamin A
supplementation for women in HIV-endemic areas
[30,31]. Despite these concerns, Fawzi et al. [31] maintain
that prenatal supplementation of vitamins B, C, and E
should be continued due to their many reported positive
effects on maternal and fetal health.
In short, studies have shown a range of potential implica-
tions of antioxidant supplementation. Some have found
reasons for concern, others have shown negligible effects,
and still others have been positive about the potential of
antioxidant supplementation as a therapy or supplemen-BMC Public Health 2009, 9(Suppl 1):S12 http://www.biomedcentral.com/1471-2458/9/S1/S12
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tal therapy for HIV-infected individuals. Despite this
range of opinions, the 2007 review by Drain et al. [22]
maintains that supplementation in individuals not receiv-
ing HAART is clearly beneficial; however, there are not suf-
ficient data to indicate whether the same can be said for
individuals receiving HAART.
Injection drug users form a particular group of interest
due to the endemic nature of HIV infection in this popu-
lation. According to the WHO, the global population of
injection drug users (IDUs) consists of approximately
15.9 million people, of which 3 million are HIV-positive.
The spread of the virus is particularly rampant in popula-
tions where injecting equipment is re-used and shared. Of
the new HIV infections, one in ten are caused by the use
of injection drugs. In Eastern Europe and Central Asia,
drug use can be attributed to 80% of all HIV infections
[34]. Thus, for the potential eradication of HIV, it is criti-
cal that this population, among others, be targeted. Fur-
thermore, oxidative stress has been implicated as a factor
in faster disease progression in HIV-positive IDUs. Lower
serum concentrations of vitamin A, compared with HIV-
negative IDUs, have also been observed [35].
A particular clinical study conducted by Jaruga et al. [28]
demonstrated a clear benefit for antioxidant therapy in
IDUs when compared with the appropriate control group.
In this study, samples were collected from a control group
of 10 healthy volunteers, a group of 15 HIV-negative
injection drug users (denoted HIV(-)) and a group of 30
asymptomatic HIV-positive injection drug users (denoted
HIV(+)). The latter HIV-positive group was divided into
two subgroups: one subgroup of 15 patients received a
placebo (HIV(+)P), while the other received a daily sup-
plement of 5000 units of vitamin A, 100 units of vitamin
E and 50 mg of vitamin C (HIV(+)V). After six consecutive
months of treatment, it was found that patients in groups
HIV(-) and HIV(+)P had significantly lower blood plasma
concentrations of vitamins A, C and E than the control
group, while individuals in the HIV(+)V group had levels
characteristic of the control group. In addition, while
there was a lack of statistical significance, the CD4+ T cell
count for HIV(+)V individuals was 100 cells/μL higher
than for those receiving a placebo. In conclusion, the
authors of the study reaffirm that the combination of
infection with HIV and lifestyle factors typical of injection
drug users (for example, a diet which is not rich in antioxi-
dants) may lead to oxidative stress, a potential factor in
AIDS development.
In the sections which follow, a mathematical model is
developed to investigate the use of antioxidants as a treat-
ment strategy for HIV. We use clinical data from Jaruga et
al. [28] to estimate parameter values for both control and
HIV(+) cases, and then test in detail the results of varying
the level of antioxidant supplementation in the HIV(+)V
group, largely through numerical bifurcation analysis. We
also include an analysis of the sensitivity of our predic-
tions to both parameter estimates and interpatient varia-
bility.
Note
Despite the benefits that can be obtained from antioxi-
dant supplementation, we maintain that the need for
accessible and affordable antiretrovirals in developing
countries is of utmost importance and must not be
neglected.
Methods
As outlined in the Background, HIV-infected CD4+ T cells
can produce HIV virions via two ROS-independent path-
ways: either directly or through the activation of NF-κB.
However, it has been shown that the combined effect of
these pathways accounts for a mere one-twentieth of the
total virion production [17]. The more substantial frac-
tion of virion production has been attributed to ROS-acti-
vated NF-κB [17]. During HIV infection, immune cells
(such as macrophages and neutrophils) are also activated,
resulting in an increase in ROS generation. Thus, infected
cells indirectly produce high levels of ROS, which in turn
directly increase the production of virions by infected
cells. Antioxidants can control this vicious cycle by reduc-
ing ROS concentrations.
To model these processes, we propose a system of differ-
ential equations which consists of four populations: unin-
fected CD4+ T cells (x), infected CD4+ T cells (y), reactive
oxygen species (r) and antioxidants (a):
where β(r) is a positive, increasing function. See Figure 1.
Uninfected CD4+
CD4+ T cells are produced by the thymus at constant rate
λx, are eliminated from the system at per-capita rate dx and
become infected through mass-action kinetics at rate β(1
- )xy, where the infection rate β is a function of r, described
below, and  is the effectiveness of drug therapy.
dx
dt
dx r x y xx =− − − λβ () ( ) 1 † (1)
dy
dt
rx y d y y =− − β() ( ) 1 † (2)
dr
dt
ky mar h r rr =+− − λ (3)
da
dt
par h a aa =+ − − λα , (4)BMC Public Health 2009, 9(Suppl 1):S12 http://www.biomedcentral.com/1471-2458/9/S1/S12
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Infected CD4+
CD4+ T cells become infected at rate β(1 - )xy. Infected
cells are removed from the system at per-capita rate dy.
Reactive oxygen species
ROS are naturally produced at constant rate λr. In the
event of infection, ROS are also produced by infected cells
at a rate proportional to the number of infected CD4+ T
cells, ky. ROS are eliminated from the system by reacting
with antioxidants at rate mar and through all other proc-
esses, including reactions with NF-κB and other mole-
cules, such as enzymes, at decay rate hrr.
Antioxidants
Antioxidants are introduced into the system via dietary
intake at constant rate λa. Plasma antioxidant levels may
be supplemented therapeutically at constant rate α. Anti-
oxidants have natural decay rate haa. Since a large fraction
of antioxidants are regenerated after reaction with ROS,
we define a new rate of antioxidant consumption, par,
where p is much smaller than m.
Infectivity
To capture ROS-activated transcription in our model, we
would like β(r) to be a saturating, increasing function of r.
For simplicity, we choose a Michaelis-Menten equation.
Therefore, we take
While several other forms of β(r) might be equally reason-
able, this expression provides a good fit to the (limited)
data derived from clinical studies (the "ROS-absent",
β(r*) and β(rp) points described in the Parameter Estima-
tion section, and illustrated in Figure 2).
Note
Many standard HIV models also incorporate an explicit
virion population. While virions are not directly modelled
in our system, the vital role that they play is not neglected:
since they are in quasi-equilibrium with the infected cells,
the concentration of virions in the system is roughly pro-
portional to that of the infected cells [36,37].
Results
Analytical results
Evaluating for the equilibria yields one biologically mean-
ingful disease-free equilibrium:
where B = λam + αm + hrha-λrp. Thus, when λr > hrrd, or
whenever the production rate of ROS exceeds their overall
removal rate, an HIV-negative individual will exhibit a
balanced ROS-antioxidant equilibrium. β()
( max )
. rb
rb b
rr
=+
−
+
0
0
half
(5)
x x
dx
y
rB B p h h h p
ah r m r
d
d
d
arr r
d
rr
dd
=
=
=− + +
=−
λ
λ
λ
0
42
2 () /
() / ,
Schematic diagram of the model Figure 1
Schematic diagram of the model. Reactive oxygen species, while not the sole means for transcription of HIV, directly 
increase the transcription rate. This results in an increased infection rate β(r).BMC Public Health 2009, 9(Suppl 1):S12 http://www.biomedcentral.com/1471-2458/9/S1/S12
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Using the next-generation matrix method from [38], we
find the basic reproductive ratio to be
which makes intuitive sense since a single infected cell at
the uninfected equilibrium will produce new infected
cells at rate β(rd)(1 - )xd, for mean lifetime 1/dy. (We note
that, in practice,  is almost always zero in this situation.)
We next examine stability of the disease-free equilibrium
using the following Jacobian:
This yields four eigenvalues
Therefore, the disease-free equilibrium is stable when R0 <
1 (from (8)).
In addition to the disease-free equilibrium, two biologi-
cally meaningful internal equilibria exist; we omit their
analytical expressions here since their complicated form
offers little insight. Instead, following parameter estima-
tion, we complete a bifurcation analysis of all three bio-
logically meaningful equilibria in the Numerical Results.
We note that our model, and the analytical results
described up to this point, could be generalized to other
factors that are produced in proportion to infected T cells
(ky  term), increase the in-host transmission rate (β(r)
term) and can be counteracted through mass-action kinet-
ics by some exogenous factor (mar term). However, in the
next section, we estimate parameters specific to ROS and
antioxidants, and further numerical results are thus spe-
cific to this case.
Parameter estimation
Developing reasonable (if uncertain) parameter estimates
is one of the most difficult aspects of theoretical immu-
R
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The β(r) curve Figure 2
The β(r) curve. The β(r) curve, denoted by the solid line, represents the rate of infection in the absence of drug therapy. The 
dashed line depicts the decrease in the infection rate due to HAART, the β(r)(1 - ) curve. The dotted line represents the max-
imum rate of infection.
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nology, and yet can be an extremely worthwhile endeav-
our [39]. In the tables and subsections which follow, we
describe our estimates for both control (HIV(-)) and HIV-
positive parameters. We examine the sensitivity of our
main results to these estimates in the Sensitivity Analysis.
The model described above includes a total of four popu-
lations and 15 parameters. Estimates of six of these
parameters (λx, dx, dy, λa, ha and ) were directly obtained
from the literature and can be found in Table 1. We use R0
and the seven clinically measured equilibrium levels from
Table 2 to deduce the other parameters (see Table 3),
except for α, which we will vary to investigate therapy.
Throughout this section and the numerical work which
follows, we will use units of cells per μL plasma (for x and
y) or molecules per μL plasma (for a and r). In estimating
parameters related to the population r, we specifically
examine the reactive oxygen species hydrogen peroxide as
it has been shown to play an important role in the activa-
tion of HIV transcription. Moreover, since ascorbic acid
(vitamin C) has been cited as a key H2O2 scavenging anti-
oxidant [40], we use it as our antioxidant for the purpose
of parameter estimation.
In this section and the work which follows, we also refer
to four cases of the infected equilibrium, which differ only
in their parameter values. Specifically, we denote (1) the
uninfected, control diet case with a "hat" (i.e.  ), (2) the
uninfected, IDU case with an asterisk (i.e. x*), (3) the
infected, placebo case with a superscript p(i.e. xp) and (4)
the infected, vitamin supplementation case with a super-
script v(i.e.  xv) (see Table 2). These populations corre-
spond to the healthy control, HIV(-), HIV(+)P and
HIV(+)V groups of Jaruga et al. [28], respectively.
Literature estimates for   and λa
It has been recommended that dietary vitamin C intake
for all individuals exceed 200 mg per day [41]. Seventy-
eight percent, or about 160 mg per day, of this amount is
absorbed by the approximately 10 L volume of plasma
and extracellular space [42]. This corresponds to an anti-
oxidant introduction rate in the control group,  , of
5.47 × 1013  molecules  μL-1  day-1
. In
order to account for the fact that injection drug users
(IDUs) may have a smaller vitamin C intake, we set the
amount of dietary vitamin C absorbed in groups HIV(-),
HIV(+)P and HIV(+)V to be 80 mg/day which yields λa =
2.74 × 1013 molecules μL-1 day-1. Both of these estimates
have a high degree of uncertainty since the pharmacoki-
netics and bioavailability of ascorbic acid are complex
[42]. These parameter values will be examined in the Sen-
sitivity Analysis to follow.
Finding xp, yp, xv and yv
The clinical data in Table 2 give only the sum of CD4+ T
cells, xp + yp and xv + yv. To find each term independently,
we combine equation (1) and equation (2), at equilib-
rium,
where λx, dx and dy are known. Thus, for the HIV(+)P case,
we find xp = 317 and yp = 43. Likewise, for the HIV(+)V
case, we find xv = 423 and yv = 37.
Estimating the function β(r) and 
The Jaruga et al. study [28] which we use to estimate cer-
tain parameters was comprised of HIV-negative individu-
als and patients on highly active antiretroviral therapy
(HAART). Since HAART reduces the rate of infection in an
HIV-positive individual, we consider the effectiveness of
this therapy in our model, denoted by . To estimate this
parameter, we use the results of a study by Manfredi et al.
[43] which examined a group of individuals of a similar
ˆ x
ˆ λa
ˆ λa
(. )
.
.
01 6
10 106
1
176 14 6 022 10
23  g
L day
molecules
mol
mol
g ⋅
×⋅ ×
μ
λxx y dx dy −−= 0, (10)
Table 1: Parameter estimates from the literature
Parameter Value Reference
λx 60.76 cells μL-1 day-1
estimated from   = λx/dx [49]
dx 0.057 day-1 [50]
dy 1 day-1 [51]
5.99 × 107 day-1 (half life = 1 ms) [52]
5.47 × 1013 molecules μL-1 day-1 [5]
λa 2.74 × 1013 molecules μL-1 day-1 estimated from [5]
ha 0.0347 day-1 (half life = 8 - 40 days, choose 20 days) [45]
R0 4.5 estimated from [36]
estimated from [43]
ˆ x
hm a r + ˆ
λa
1
3BMC Public Health 2009, 9(Suppl 1):S12 http://www.biomedcentral.com/1471-2458/9/S1/S12
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mean age to those of the Jaruga et al. study [28] (33.9 ± 1.6
vs 27 ± 9), the majority of whom were also IDUs [43].
Twelve months of treatment were shown, on average, to
increase these patients' CD4+ T cell counts from 231 ± 87
cells/μL to 345 ± 62 cells/μL, which is approximately the
same level as in the HIV(+) groups in Jaruga et al. [28].
Using the concentration of CD4+ T cells before and during
therapy as a proxy to estimate effectiveness, and assuming
that this effectiveness has reached equilibrium after twelve
months, we set  to be  . We note that this over-
all measure of the effectiveness of therapy includes phar-
macological effectiveness, as well as the adherence of the
IDU group.
We are ultimately interested in modelling the three IDU
populations, HIV(-), HIV(+)P and HIV(+)V. Therefore, we
take R0 to be defined at the HIV(-) case where  = 0. Using
(6), we find R0 at this equilibrium to be:
Given the parameter values in Table 1, this yields β(r*) =
0.00422. Since NF-κB activation results in a 20-fold
increase in HIV transcription [17], we let β(r*) = 20b0 and
thus b0 = 0.000211. From the disease-free IDU equilib-
rium we therefore have two points with which to fit the
β(r) curve, β(r*) and β(0). A third point is obtained from
the HIV(+)P equilibrium. In this case, since y ≠ 0, dy = 1
and β(r)(1 - ) =   at equilibrium (equation (2)), β(rp) =
 = 0.00473.
These three points on the β(r) curve allow us to fit the two
other free parameters, yielding bmax = 0.00621 and rhalf =
3.57×1013. This fixes the function β(r) (see Figure 2)
which models the rate of infection in the absence of drugs.
A second curve modelling the effect of therapy, β(r)(1 - ),
can be used to iteratively estimate a further free parameter
hr. The procedure we use is to estimate a value of hr, then
follow through the steps described for estimating λr, p, m
and k. This allows for numerical estimates of four more
parameters and ultimately yields an estimate for rv, the
concentration of ROS at the HIV(+)V equilibrium. We
then iteratively adjust our initial estimate of hr such that
βrv(1 - ) = 1/xv lies along the dashed curve in Figure 2. This
procedure yields hr = 1.66 × 107 day-1.
Estimating λr, p, m and k
Given that m  + hr = 5.99 × 107 day-1 (Table 1), knowing
 and assuming hr, we directly compute m = 1.27 × 10-6.
In addition, since y = 0 at the uninfected equilibrium,
equation (3) at equilibrium yields
We assume that λr, the rate at which ROS are naturally
produced, is constant for all individuals. In contrast, λa
represents the dietary influx of antioxidants, and we thus
assume that λa is constant for the HIV(-) and HIV(+)
groups, but may differ for the control group. Therefore, we
use a* and r* to find λa for the IDU groups. Thus, we must
first find r*. Using (3) at equilibrium,
1 231
345
1
3 −≈
R
r x
dxdy
0 =
βλ (* )
.
1
x
1
1 xp() −†
ˆ a
ˆ a
λ
μ
rr ma h r =+
=×
−−
()
.. 18 6 1 0
21 1 1  molecules  L  day
Table 2: Equilibrium populations from the literature
Parameter Value Reference
Healthy control group
1,066 cells/μL[ 4 9 ]
51.5 ± 4.95 μM[ 5 3 ]
56.8 ± 4.5 μM[ 2 8 ]
HIV(-) (IDU)
x* 1,066 cells/μL[ 4 9 ]
a* 12.1 ± 1.8 μM[ 2 8 ]
HIV(+)P (IDU)
xp + yp 360 cells/μL[ 2 8 ]
yp 43 cells/μL from equation (10)
ap 8.2 ± 1.8 μM[ 2 8 ]
HIV(+)V (IDU)
xv + yv 460 cells/μL[ 2 8 ]
yv 37 cells/μL from equation (10)
av 49.0 ± 5.0 μM[ 2 8 ]
ˆ x
ˆ r
ˆ a
Table 3: Parameter estimates
Parameter Value
b0 0.000211 (cell/μL)-1 day-1
bmax 0.00621 (cell/μL)-1 day-1
rhalf 3.57 × 1013 molecules μL-1
hr 1.66 × 107 day-1
λr 1.86 × 1021 molecules μL-1 day-1
K 1.49 × 1019 molecules cell-1 day-1
M 1.27 × 10-6 (molecule/μL)-1 day-1
α variable molecules μL-1 day-1
P 5.04 × 10-14 (molecule/μL)-1 day-1BMC Public Health 2009, 9(Suppl 1):S12 http://www.biomedcentral.com/1471-2458/9/S1/S12
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The parameter p, which should be constant for all individ-
uals, is found using (4) at the control equilibrium, i.e., for
y = 0 and α = 0:
From equation (4) at the HIV(+)P equilibrium,
We find our final parameter, k, from equation (3) at the
HIV(+)P equilibrium:
Finally, from equation (3) at the HIV(+)V equilibrium:
Numerical results
Using the parameters in Tables 1 and 2, the equilibria of
our model were found analytically. At these parameter
values and antioxidant supplementation levels, only one
biologically meaningful internal equilibrium exists, and
this equilibrium agrees well with the CD4+ T cell and anti-
oxidant concentrations in Jaruga et al. [28], as illustrated
in Figure 3. In the first two columns, we compare the con-
trol individuals with the HIV-negative IDUs whose life-
style, including a poorer diet, is a closer control to the
HIV-positive IDUs in the Jaruga et al. study [28]. As
expected, a significant increase in ROS and decrease in
antioxidant concentrations is observed in the HIV(-)
group. Furthermore, in the presence of HIV infection and
absence of antioxidant treatment, these trends continue:
the concentrations of ROS and antioxidants further
increase and decrease, respectively, in the HIV(+)P group.
This is combined with a sizable drop in the total CD4+ T
cell concentration from 1066 cells/μL to 360 cells/μL.
With daily antioxidant supplementation of approximately
116 mg, the antioxidant concentrations increase and ROS
concentrations decrease, but neither quite reach the levels
observed in control individuals. Although at this level of
supplementation the analytically predicted equilibrium
does reach the CD4+ T cell equilibrium of 460 cells/μL
found for the HIV(+)V group in Jaruga et al. [28], it is
important to note that this equilibrium point is unstable,
as described in greater detail below.
Before examining the benefits and limitations of vitamin
supplementation, we test our analytical results using
numerical integration (MATLAB ®, The MathWorks Inc.)
for HIV-negative IDUs who subsequently become infected
with HIV. In the absence of vitamin supplementation,
such an individual would display trends similar to those
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The analytical results for the control, HIV(-) and HIV(+)P groups Figure 3
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observed in Figure 4: an initially healthy concentration of
CD4+  T cells is followed, upon infection, by a sharp
decline in the number of uninfected CD4+ T cells which
eventually equilibrates at a significantly lower concentra-
tion of 317 cells/μL. In addition, the ROS concentration
increases to an equilibrium value well beyond normal lev-
els and the antioxidant concentration decreases. Note that
in Figure 4b the antioxidant concentration is scaled by a
factor of ten so that these trends can be more clearly
observed.
Next, we examine the behaviour of our model when
patients are given moderate daily vitamin supplementa-
tion. For this case, our model suggests that an HIV-posi-
tive IDU's T cell count can increase, with a concomitant
reduction of ROS. However, the magnitude and nature of
these changes are dependent upon the level of supple-
mentation. Notice, for example, the outcomes of two dif-
ferent supplementation levels in Figure 5. When we
supplement the diet with 58 mg of absorbed antioxidants
per day, an increase in the level of uninfected CD4+ T cells
(to 345 cells/μL) is observed. However, as we noted in the
discussion of Figure 3, we are unable to reach the clinical
mean, xv, found in Jaruga et al. [28]. Instead, the level of
supplementation required for a mean CD4+ count of 460
cells/μL, 116 mg/day, results in the oscillatory dynamics
illustrated in Figure 5b.
We further investigate this interesting behaviour through
numerical bifurcation analysis, substituting our parame-
ter values into the analytically-determined eigenvalues of
the Jacobian. Using the vitamin supplementation level, α,
as a bifurcation parameter, we observe that increasing α
causes an increase in the concentration of uninfected cells
and a decrease in ROS concentrations, as expected (Figure
6). However, there exists a critical vitamin supplementa-
tion level, αc = 2.63×1013 molecules/μL per day (approxi-
mately 78 mg/day), at which the internal equilibrium
undergoes a supercritical Hopf bifurcation: the stable
internal equilibrium for α <αc becomes a stable limit cycle
for α > αc (Figure 6). Further analysis reveals three addi-
tional bifurcations at values of α > α c; however, these are
of little clinical relevance.
These bifurcation diagrams also confirm what we found
in the Analytical Results: the disease-free equilibrium is
stable when R0 < 1. This occurs when r <8.16 × 1012 mol-
ecules/(μL day) (shaded region in Figure 6b), with α ≥
4.59 × 1013 molecules/μL per day, or a total supplementa-
tion level greater than 134 mg/day. Our model therefore
suggests that there exists a supplementation level at which
an HIV(+) individual could theoretically clear all infected
cells in plasma. Yet, this only occurs when the concentra-
tion of ROS is well below normal levels, and would there-
fore not be physiologically possible.
The behaviour of the limit cycle is further examined in the
region where α > αc by integrating our system numerically
for 600 days and measuring the time between the last two
peaks. As shown in Figure 7, when vitamin supplementa-
tion levels increase above αc, the period of the oscillations
increases dramatically. Interestingly, as α changes, so does
the behaviour of the limit cycle, depicted in the insets of
Figure 7. For supplementation levels close to αc, the oscil-
An initially uninfected IDU who subsequently becomes infected Figure 4
An initially uninfected IDU who subsequently becomes infected. Here we observe a significant drop in uninfected 
CD4+ T cell levels (solid line) characteristic of the infection. An equilibrium is eventually reached where x = 317 cells/μL, y = 43 
cells/μL, r = 1.09 × 1014 molecules/μL and a = 4.94 × 1012 molecules/μL. The concentration of infected cells is represented by 
the dashed line and ROS by the dashed-dotted line. For clarity the time course of antioxidants has been scaled; the dotted line 
plots 10a.
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lation is moderate, with symmetrical peaks and troughs.
Higher levels of α, on the other hand, result in severe
oscillations, characterised by extended intervals of high
CD4+ T cell counts followed by sharp, short-lived periods
in which the patient is in an immunocompromised state.
Regardless of the shape of these oscillations, a therapeutic
regimen which causes repeated periods of immunosup-
pression would not be clinically advisable. Thus, our
model predicts the existence of a maximum vitamin sup-
plementation level, αc, beyond which further supplemen-
tation might be detrimental.
To better understand this threshold behaviour, we look at
xmax, which we define to be the maximum attainable sta-
ble equilibrium concentration of uninfected T cells; that
is, the equilibrium value of x when α = αc (Figure 6). Using
the parameter values as indicated in the Parameter Estima-
tion section, xmax = 369 cells/μL, which falls short of the
mean value xv = 423 cells/μL reported in Jaruga et al. [28].
Uninfeted (solid line) and infected (dashed line) cell concentration for an initially infected IDU who begins vitamin supplemen- tation on day 50 Figure 5
Uninfected (solid line) and infected (dashed line) cell concentration for an initially infected IDU who begins 
vitamin supplementation on day 50. In (a), a stable equilibrium results from a supplement of α = 2.0 × 1013 molecules/(μL 
day) which corresponds to 58 mg of daily vitamin C supplementation. In (b), a periodic cycle appears when α = 4.0 × 1013 mol-
ecules/(μL day), corresponding to 116 mg of daily vitamin C supplementation.
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Bifurcation diagrams of our model of the uninfected T cells and ROS Figure 6
Bifurcation diagrams of our model of the uninfected T cells and ROS. A solid line implies a stable equilibrium and a 
dashed line implies an unstable equilibrium. In (a), we indicate the maximum attainable stable concentration of uninfected cells, 
xmax (dotted black line). The dotted horizontal line in (b) indicates the ROS level observed in non-IDU control individuals. We 
denote the ROS concentration for which the disease-free equilibrium becomes stable with the grey box.
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To investigate this difference further, we examined the
extent to which xmax is sensitive to assumptions regarding
our parameter values.
Sensitivity analysis
We examine the sensitivity of our model to several param-
eters for which our assumed values have a high degree of
uncertainty, or which may display significant interpatient
variability. In particular, we look at how the maximum
attainable uninfected CD4+  T cell concentration, xmax,
changes as a result of varying parameters. In each case, to
compute xmax, we performed a numerical bifurcation anal-
ysis as illustrated in Figure 6, increasing α until the stabil-
ity of the internal equilibrium is lost.
We test for sensitivity in two ways. First, we examine the
sensitivity of xmax to the parameter values from the litera-
ture which we initially assumed in the Parameter Estima-
tion section and upon which further parameter estimates
depend. In a second analysis, we look at the sensitivity of
xmax to interpatient parameter variation. In both sections,
we examine the trends in xmax as well as the corresponding
concentrations of infected T cells, ROS and antioxidants
when a parameter of interest is varied.
Sensitivity to initial parameter estimates
In this section, we vary five parameters which have a high
degree of uncertainty in order to test the overall sensitivity
of our results to these assumed parameter values. In cases
where the values of other parameters depend on these ini-
tial estimates, we subsequently recompute all other
dependent model parameters, using the method
described in the Parameter Estimation section.
Dietary antioxidant intake of the controls
First, due to the natural variability surrounding the diet of
control individuals and the uncertainty regarding the
The period of the limit cycle as a function of vitamin supplementation levels Figure 7
The period of the limit cycle as a function of vitamin supplementation levels. As the vitamin supplementation level 
increases beyond αc = 2.63 × 1013 molecules/μL per day, changes in the dynamics of the limit cycles can be observed. Insets (a) 
and (b) show the limit cycle at α = 2.8 × 1013 and α = 4.45 × 1013, respectively. In the insets, the uninfected and infected cell 
concentrations are respectively represented by the solid and dashed lines.
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amount of antioxidants absorbed, we vary  , the
amount of antioxidants absorbed from the diet of control
individuals. Note that, when   changes, so do our esti-
mates of parameters hr, m, k, bmax, rhalf and p. In addition,
equilibria r*, rp and rv were altered. From Figure 8a, it may
be observed that, as   increases, our model predicts a
reduction in rv, while xmax increases only slightly: a 200%
increase in   causes a 21% increase in xmax.
Dietary antioxidant intake of IDUs
For reasons similar to those posed above, we secondly
analyse the sensitivity of λa, the amount of antioxidants
absorbed from the diet of IDUs, and find that xmax
decreases modestly as λa increases (Figure 8b). Note that,
when λa changes, so do our estimates of parameters hr, m,
k, bmax and rhalf . Equilibria r*, rpand rv were altered as well.
This restricts the range we can examine; when λa < 0.048 g
day-1, the positivity of certain parameter values is lost.
Importantly, close to the lowest possible value of λa, we
are able to replicate the HIV(+)V Jaruga et al. [28] results;
that is, xv + yv = 460.
Again, a very modest change is observed: a 220% parame-
ter increase results in a 21% decrease in xmax.
Drug effectiveness
Third, we vary drug effectiveness due to our uncertainty
surrounding its estimate and its dependence upon the
treatment regimen. When  changes, so do our estimates of
parameters hr, m, k, R0, bmax and rhalf . Equilibria r* and rv
were altered as well. In Figure 9a, an increasing  is shown
to yield a decreasing xmax, although again xmax is moder-
ately sensitive to this parameter: a 31% increase in  causes
a 14% decrease in xmax. Note that, at higher values of  than
illustrated in Figure 9a, the stability of the internal equi-
librium is lost, whereas at lower values the positivity of
certain parameters is lost. This restricted range of  only
applies to our estimates of mean drug effectiveness for the
IDU group in the Jaruga et al. [28] study; interpatient var-
iation in  is possible over a much wider range, as described
in detail below.
Basic reproductive ratio
Fourth, since there is uncertainty surrounding the value of
R0, the results of a range of parameter values are analysed.
Note that, when R0 changes, so do our estimates of param-
eters hr, m, k, R0, bmax and rhalf . Equilibria r* and rv were
altered as well. We observe in Figure 9b that, as R0
increases by 17%, xmax increases by 24%; therefore, we
find that xmax is somewhat sensitive to changes in R0. Val-
ues of R0 lying below the range presented in Figure 9b
cause the disease-free equilibrium to regain stability,
whereas those that are higher result in negative parameter
values.
ROS removal
Finally, since the removal rate of ROS is extremely rapid
and is therefore difficult to compute, we analyse the sys-
tem for varying removal rates,  . We find that our
results are completely insensitive to changes in 
(data not shown), since the values of the subsequently
computed parameters, namely hr, m and k, exactly com-
pensate for this change.
ˆ λa
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Sensitivity analyses of (a)   and (b) λa Figure 8
Sensitivity analyses of (a)   and (b) λa. The equilibrium concentration of uninfected cells is represented by the solid line, 
infected cells by the dashed line, ROS by the dashed-dotted line and antioxidants by the dotted line. We also include the level 
of antioxidant supplementation, αc (thin, grey line). Levels obtained at the default parameters values (xv, yv, rv and av) are indi-
cated by dots.
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Despite these cascading changes to subsequently com-
puted parameters in response to changes in  , λa or , we
find that xmax is fairly insensitive. However, the value of
xmax is somewhat sensitive to our initial assumption of the
in-host  R0 for HIV, which is interesting given that the
value of this parameter is not well known [36]. In con-
trast, the predicted ROS concentration at α = αc is very sen-
sitive to our initial assumptions regarding these
parameters. We are able to replicate clinical results under
the assumption that the IDU group has a very low dietary
intake of antioxidants, corresponding to 48 mg absorbed
per day.
Sensitivity to interpatient variability
In this section, we quantify the sensitivity of our model to
interpatient variation for several parameter values. Unlike
in the previous section where dependent parameter values
were recalculated in response to variation in an assumed
parameter, here we only vary the parameter of interest and
hold all other parameters constant, except α which we
vary in order to find αc as before.
Drug effectiveness
Our first parameter of interest is drug effectiveness, since
varies from patient to patient due to differences in HIV
progression and levels of adherence. As anticipated, our
model is sensitive to the level of effectiveness, with xmax
(solid line) rising with increasing effectiveness (Figure
10a). Furthermore, our model suggests that increasing a
patient's drug effectiveness from   to 0.7 is sufficient to
drive the plasma concentration of infected cells to unde-
tectable levels, as is observed in aggressive HAART [44].
Increased drug effectiveness also results in a reduction in
the level of antioxidant supplementation required to real-
ize xmax and increases the chance of oversupplementation.
Thus, our model predicts, interestingly, that antioxidant
supplementation should be reduced in patients who
exhibit strong adherence, although some level of supple-
mentation would continue to be beneficial.
Basic reproductive ratio
Second, we test the sensitivity of our results to R0, since
this parameter could also display interpatient variability
due to differences in immunocompetence, disease pro-
gression and other factors. As we observe in Figure 10b,
although the concentration of ROS decreases, xmax is rela-
tively insensitive to changes in R0 over an extremely wide
range: an increase from 0 to 35 results in a mere 3%
increase in xmax.
Natural ROS production
In the formulation of our model, we made the assump-
tion that the natural rate of ROS production, λr, was the
same for all individuals. Therefore, we thirdly examine the
effect of a varying interpatient λr. In Figure 11, it may be
observed that, despite an increasing λr, ROS concentra-
tions (dashed-dotted line) initially decrease and therefore
xmax  (solid line) initially increases. This trend can be
attributed to significant increases in antioxidant supple-
mentation levels (thin, grey line); as λrincreases, higher
values of αc are possible without losing the stability of the
equilibrium. However, since physiological constraints
would presumably impose some limit on the degree of
the vitamin supplementation possible, we set a maximum
antioxidant supplementation level of 2.0 × 1014 molecules
μL-1 day-1, which is approximately 586 mg/day, absorbed
into the bloodstream. The quantitative value of this limit
ˆ λa
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3
Sensitivity analyses of (a)  and (b) R0 Figure 9
Sensitivity analyses of (a)  and (b) R0. The concentration of uninfected cells is represented by the solid line, infected cells 
by the dashed line, ROS by the dashed-dotted line and antioxidants by the dotted line. We also include the level of antioxidant 
supplementation, αc (thin, grey line). Levels obtained at the default parameter values are indicated by dots.
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has been chosen arbitrarily to illustrate the qualitative
effects of the physiological limit which presumably exists.
Thus, the increases in xmax continue until α reaches our
imposed maximum, which in this example occurs when λr
= 5.65 × 1021 molecules μL-1 day-1. Further increasing λr,
combined with a constant α level, results in a significantly
increasing ROS concentration which causes xmax  to
decrease. We address this interesting qualitative predic-
tion further in the Discussion.
Dietary antioxidant intake of IDUs
Lastly, we examine the effect of a varying dietary antioxi-
dant intake and find that our results are insensitive to this
variation, the only change being an alteration in the vita-
min supplementation level required to achieve xmax (data
not shown).
Discussion
We have developed and analysed a simple model of the
interactions between CD4+ T cells, reactive oxygen species
and antioxidants. Verifying the results of various clinical
studies, our model predicts that moderate levels of anti-
oxidant supplementation in HIV-positive IDUs can lead
to an increase in uninfected CD4+ T cell concentrations.
However, our model also suggests that excessive supple-
mentation could cause fluctuating T cell concentrations in
these individuals. For example, consider the limit cycle in
Figure 5b: in this case, a patient's immunological response
is periodically compromised - characterized by a low con-
centration of uninfected CD4+ T cells - leaving the individ-
ual vulnerable to opportunistic infections.
In an effort to understand this periodic behaviour, we take
a closer look at the system dynamics when the level of
antioxidant supplementation is above the critical level, αc,
in Figure 12. In this figure, populations during the limit
cycle are rescaled to facilitate comparison, while white
vertical bars delineate the peak and trough concentrations
of infected T cells. The most direct result of an increase in
antioxidant supplementation is first an increase in the
antioxidant concentration (dotted line) and a decrease in
ROS (dashed-dotted line). These two effects produce a
concomitant increase in uninfected cells (solid, black
line) and reduction in infected cells (dashed line). As the
concentration of uninfected cells increases, the infection
rate per infected cell (β(r)x, grey line), reaches high levels,
allowing both infected cell and ROS concentrations to
increase sharply. These increases are short lived in part
because of the extremely short half-life of ROS, and due to
a rapid reduction in β(r)x. As ROS and infected cell con-
centrations plummet, the cycle is allowed to repeat. One
hypothesis is that when the level of antioxidant supple-
mentation is too high, the infection rate β(r)x reaches too
high a peak to allow for a stable equilibrium.
Regardless of its cause, the appearance of a limit cycle in
our model could explain why some clinical studies show
no improvement in patients' average CD4+ T cell concen-
trations: it is plausible that high supplementation levels
could cause fluctuating T cell counts which are then sensi-
tive to the details of measurement timing, leading to the
conclusion that antioxidant supplementation has no
immunological benefit for HIV-positive patients.
Since antioxidant supplementation levels above a critical
value,  αc, have the potential to pose difficulties for
patients, we turn our attention to the stable equilibria
obtained when α <αc. We examined in particular the max-
imum concentration of uninfected CD4+ T cells, xmax,
which could be obtained in principle as a stable equilib-
rium via antioxidant supplementation. We found xmax to
Sensitivity analyses of (a)  and (b) R0 for interpatient variability Figure 10
Sensitivity analyses of (a)  and (b) R0 for interpatient variability. The concentration of uninfected cells is represented 
by the solid line, infected cells by the dashed line, ROS by the dashed-dotted line and antioxidants by the dotted line. We also 
include the level of antioxidant supplementation, αc (thin, grey line). Levels obtained at the default parameter values are indi-
cated by dots.
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be relatively insensitive to moderate variation in five ini-
tial parameter estimates, particularly when subsequent
parameter estimates were changed as a result of these
alternative assumptions. This insensitivity is presumably
because subsequent parameters act to compensate for
alternative assumptions, since we set parameters to match
the clinically-observed equilibria. These compensatory
changes also explain why the results described in the anal-
ysis of the sensitivity to initial parameter estimates seem
counter-intuitive; for example, as our initial assumption
for the in-host R0 increases, xmax also increases (Figure 9b).
In contrast, interpatient variability results in a higher
degree of sensitivity for certain parameters, as expected.
We note that xmax is unlikely to be achieved in practice,
since the required level of precision in the supplementa-
tion level would be impossible.
Interestingly, our sensitivity analysis revealed that even
when our initial parameter estimates were varied, the
mean T cell count observed by Jaruga et al. [28] after six
months of antioxidant therapy was higher than any stable
equilibrium value predicted by our model, except when
considering exceptionally low values of λa. In the region
of instability, however, values equivalent to the clinical
data were frequently observed. For example, in Figure 13,
we present an example in which the sum of uninfected
and infected CD4+ T cells at six months, 479 cells/μL,
exceeds the 460 cells/μL found in Jaruga et al. [28]. This
was achieved with our default parameters and antioxidant
supplementation of 2.87 × 1013 molecules/μL per day, or
about 84 mg of absorbed antioxidants per day. This out-
come is anecdotal and highly dependent upon the
amount of vitamin C absorbed; however, it illustrates the
potential sensitivity of clinical results to the details of
measurement timing.
To further investigate the benefits of antioxidant supple-
mentation, we hope that future work could see the model
extended to include appropriate pharmacokinetics of
antioxidants. In its present form, our model considers α to
remain constant over time. If we included the full dynam-
ics of antioxidant concentrations after an oral dose,
including varying the antioxidant decay rate with plasma
concentration [45], we predict that the oscillatory behav-
iour observed here would be exacerbated. Either standard
pharmacokinetic modelling [46] or impulsive differential
equations [39] could be used to examine such effects.
It would also be interesting to explore the effects of enzy-
matic antioxidants: glutathione peroxidase and catalase,
for example. Both of these enzymes are used in the elimi-
nation of hydrogen peroxide (H2O2), but are not con-
sumed by these reactions. Their short half-lives (less than
10 minutes) [47,48], however, could further exacerbate
the variability already observed in the simple model.
Conclusion
While antioxidant supplementation may not be a long
term solution for HIV-positive IDUs, our model suggests
that moderate doses of antioxidants may temporarily
Sensitivity analysis of λr for interpatient variability Figure 11
Sensitivity analysis of λr for interpatient variability. The concentration of uninfected cells is represented by the solid 
line, infected cells by the dashed line, ROS by the dashed-dotted line and antioxidants by the dotted line. We also include the 
level of antioxidant supplementation, αc (thin, grey line). Levels obtained at the default parameter value are indicated by dots. 
Stability is lost for lower values of λr than those illustrated.
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boost uninfected CD4+ T cell concentrations. This might
enable HIV-positive individuals to lengthen the interval
before costly drugs with severe side effects become neces-
sary. These results could have implications for infected
individuals in HIV-endemic areas, since dietary antioxi-
dant intake depends on the availability of adequate anti-
oxidant-rich produce. Moreover, where access to
antiretroviral therapy is limited or non-existent due to
economic constraints, a significantly more affordable vita-
min supplementation therapy could potentially provide
A closer look at the dynamics of the stable limit cycle Figure 12
A closer look at the dynamics of the stable limit cycle. The concentration of uninfected cells is represented by the solid 
black line, infected cells by the dashed line, ROS by the dashed-dotted line and antioxidants by the dotted line, each rescaled 
for comparison. The solid grey line denotes β(r)x. White vertical bars delineate maxima and minima in infected cell concentra-
tions.
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The oscillatory dynamics of the system when 84 mg of the daily vitamin supplement is absorbed Figure 13
The oscillatory dynamics of the system when 84 mg of the daily vitamin supplement is absorbed. We see that six 
months after the start of supplementation, we reach CD4+ T cell levels observed in the Jaruga et al. study. The concentration of 
uninfected cells is represented by the solid black line, infected cells by the dashed line.
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some limited benefit. Of course we emphasize that this in
no way reduces the need for accessible and affordable
antiretrovirals in developing countries.
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